In Romania suport voluntariat Dna. Maria - 0748390309 Luni - Vineri: intre orele 17.00 - 21.00 Sambata intre orele 15.00 - 19.00 Duminica doar urgente Email Suport in India (24 x 7) Dl. Jasminder - +919811604429 Dna. Jasleen - +919811604479
USA TOLL FREE NUMBER (24x7) - 1800-231-5109
+91-9811604429, +91-9811604479CONTACT US

You have no items in your shopping cart.

Product was successfully added to your shopping cart.

LEDIKAST - Ledipasvir 90 mg and Sofosbuvir 400 mg Tablets

Be the first to review this product

Quick Overview

LEDIKAST - Ledipasvir 90 mg and Sofosbuvir 400 mg Tablets

LEDIKAST Tablets Specification :

Brand Name : LEDIKAST 
Contents: Ledipasvir and Sofosbuvir
Marketed by : Aprazer Health Care
Manufactured by : Natco Pharma Limited
Strength - Each film-coated tablet Contains : 90 mg Ledipasvir and 400 mg Sofosbuvir
Form : Tablets
Packing : Pack of 28 Tablets

Availability: In stock




A combination of a fixed dose containing Ledipasvir and Sofosbuvir is found in Ledikast for oral administration. This combination is found with 2 doses of a fixed combination with the potency of 90mg Ledipasvir and 400mg Sofosbuvir, where Ledipasvir is an HCV NS5A inhibitor and Sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase. Natco Pharma Limited a leading pharmaceutical company manufactures these tablets to provide affordable medicines to all patients in plastic bottles containing 28 tablets each. One can buy Ledikast online from any part of the world especially USA, Russia, Peru China and Romania.

Uses and Treatment Duration

The Ledikast tablets are used by doctors to reduce the chronic Hepatitis C (CHC) genotype 1infection from the body and later from the blood stream in a time span of 12 weeks in adults. Ledikast is a fixed dose combination tablet that contains ledipasvir and sofosbuvir. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase. Relapse rates are affected by baseline host and viral factors that differ between treatment durations for certain subgroups.

Recommended Dosage

Ledikast is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet and must be taken as prescribed. Although, the recommended dosage of Ledikast is one tablet taken orally once daily with or without food.


Each tablet contains 90mg of ledipasvir and 400mg of sofosbuvir.

Contents and Colours:

Each film coated tablet contains 90mg of ledipasvir and 400mg of sofosbuvir. The tablet includes the following inactive ingredients:

 Colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.

 The tablet is film-coated with a coating material that contains the following inactive ingredients: Yellow Oxide of Iron, polyethylene glycol, polyvinyl alcohol, talc, FD&C Blue #2 and titanium dioxide IP.

Colour: Yellow oxide of Iron, Titanium Dioxide IP and FD&C Blue#2

Ledikast is available as Green colored, oval shaped, film-coated tablet debossed with “SL” on one side and plain on other side of the tablet.

Mechanism of Action

Ledikast is a fixed-dose combination of ledipasvir and sofosbuvir which are directing antiviral agents against the hepatitis C virus. Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication, whereas Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is also required for viral replication.


As Ledikast contains ledipasvir and sofosbuvir, any interactions that have been identified with these agents individually might also occur with Ledikast.

Ledipasvir is an inhibitor of the drug transporters P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of co-administered substrates for these transporters.

Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS331007 is not. P-gp inducers, for example, rifampin or St. John’s wort, which may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of Ledikast, and the use with P-gp inducers is not recommended with Ledikast.


Based on drug interaction studies conducted with individual drugs Ledipasvir or Sofosbuvir or combination of Ledipasvir + Sofosbuvir, no clinically significant drug interactions have either been observed or are expected when Ledipasvir + Sofosbuvir is used with the following drugs individually: abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ ritonavir, efavirenz, emtricitabine, lamivudine, methadone, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or verapamil.


No specific antidote is available for overdose with Ledikast. If overdose occurs the patient must be monitored for evidence of toxicity.


  • 28 tablets packed in a bottle.
  • One bottle and one literature housed in a carton.
  • Store below 30°C.

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

  1. Be the first to review this product

Write Your Own Review

This is custom tab. You can add custom tab as an attribute for entire products, or for each categories. You can add CMS content such as sizing guide or videos to enhance product detail.